These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Late-Stage 18O Labeling of Primary Sulfonamides via a Degradation-Reconstruction Pathway

submitted on 08.01.2020, 20:55 and posted on 09.01.2020, 16:54 by Sean Reilly, Frank Bennett, Patrick Fier, Sumei Ren, Neil A. Strotman
A late-stage 18O labeling approach of sulfonamides that employs the corresponding unlabeled molecule as the starting material was developed. Upon deamination of the sulfonamide, a sulfinate intermediate was isotopically enriched using eco-friendly reagents H218O and 15NH3(aq) to afford a M+5 isotopologue of the parent compound. This degradation-reconstruction approach afforded isolated yields of up to 96% for the stable isotope labeled (SIL) sulfonamides, and was compatible with multiple marketed therapeutics, including celecoxib, on a gram scale. The SIL products also exhibited no 18O/16O back exchange under extreme conditions, further validating the utility of this green strategy for drug labeling for both in vitro and in vivo use. This procedure was also adapted to include pharmaceutically relevant methyl sulfones by using 13CH3, affording M+5 isotopic enrichment, thereby illustrating the broad utility of this methodology.


Email Address of Submitting Author


Merck & Co., Inc


United States of America

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest


Logo branding